Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 9993430 Tablet formulation comprising semaglutide and a delivery agent

Patent 9993430 was granted and assigned to Novo Nordisk on June, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Currently, there are no issues on this topic.

Find more entities like US Patent 9993430 Tablet formulation comprising semaglutide and a delivery agent

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo